
Gautam N Shenoy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/912607/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunology Research, 2015, 3, 1269-1278.	1.6	84
2	Sialic Acid–Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. Journal of Immunology, 2018, 201, 3750-3758.	0.4	77
3	Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunology Research, 2018, 6, 236-247.	1.6	61
4	Inducible nitric oxide synthase is a major intermediate in signaling pathways for the survival of plasma cells. Nature Immunology, 2014, 15, 275-282.	7.0	50
5	Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. , 2021, 9, e003148.		18
6	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	1.0	16
7	Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment. Blood Advances, 2017, 1, 1263-1273.	2.5	15
8	Recruitment of Memory B Cells to Lymph Nodes Remote from the Site of Immunization Requires an Inflammatory Stimulus. Journal of Immunology, 2012, 189, 521-528.	0.4	12
9	Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. Immunological Investigations, 2020, 49, 726-743.	1.0	11
10	Tumor-Associated Exosomes: A Potential Therapeutic Target for Restoring Anti-Tumor T Cell Responses in Human Tumor Microenvironments. Cells, 2021, 10, 3155.	1.8	11
11	Inhibition of Terminal Differentiation of B Cells Mediated by CD27 and CD40 Involves Signaling through JNK. Journal of Immunology, 2010, 185, 6499-6507.	0.4	7
12	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins. Scientific Reports, 2021, 11, 17853.	1.6	7
13	Preclinical evaluation of cancer immune therapy using patientâ€derived tumor antigenâ€specific T cells in a novel xenograft platform. Clinical and Translational Immunology, 2021, 10, e1246.	1.7	4
14	When Little Things Make a Big Difference. Immunological Investigations, 2020, 49, 692-697.	1.0	3